AzTrials
AzTrials

Spinal FusionTAPISNCT07218133

Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery

A study testing Auricular vagus nerve stimulation in people with Spinal Fusion and Hyperglycemia, run by Alexander T. Yahanda at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Auricular vagus nerve stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
1 siteUnited States
Study dates
8 Oct 2025to Jun 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Long-segment spinal fusions (defined as constructs spanning at least L2-pelvis for thoracolumbar fusions or C2-T2 for cervical fusions)
  • Ability to undergo a reliable neurologic examination and pain assessments

Who cannot join

  • Patients <18 years of age
  • Shorter-segment spinal fusions than those described above
  • Undergoing current active cancer therapy
  • Undergoing treatment with immunosuppressive drugs
  • Additional spinal surgery within past 6 months
  • Sustained bradycardia or presence of pacemaker
  • History of substance abuse

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Alexander T Yahanda, MD, MPHS contact

3143690198

ayahanda@wustl.edu

United States1 site, 1 recruiting
  • Washington University School of Medicine

    St Louis, Missouri, 63110

    Alexander T Yahanda, MD, MPHS, 2604946828, ayahanda@wustl.edu

    Eric C Leuthardt, MD

    Recruiting

Other trials in United States

About this study

This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management.

Read the detailed description

Long-segment spinal fusions are effective interventions to relieve pain, neurological compromise, or disability related to a variety of causes of advanced spinal degeneration or spinal deformity. Despite advancements in minimally invasive spine surgery, revision of prior instrumentation, correction of coronal or sagittal imbalance, bony decompression, and multilevel arthrodesis often must be performed via open surgery. While these procedures can produce excellent results with regards to postoperative alignment, neural decompression, and functional improvement, they are long and invasive cases requiring large incisions and extensive soft tissue dissection and osseous manipulation. As such, postoperative adverse events or complications are common (e.g., DVT/PE, wound healing problems, infection, nerve stretch injury, etc.). These patients almost universally experience significant postoperative pain, require postoperative rehabilitation, and are at high-risk for hospital readmissions. Moreover, the sterile trauma from long-segment spinal surgeries is a tremendous systemic inflammatory stimulus that yields downstream sequelae such as hyperglycemia, elevated inflammatory markers (e.g. cytokines), signs of microvascular ischemia, and other stress-related outcomes. Attempts to control this inflammation and reduce the adverse effects of these surgeries are lacking, particularly with respect to non-pharmacologic options.

Vagal nerve stimulation (VNS) is a promising emerging modality by which the body's systemic inflammatory response may be attenuated. Importantly, VNS may be successfully applied via noninvasive auricular stimulation. This technique has been trialed as non-pharmacologic pain control adjunct after multiple types of surgeries or painful medical events, but none as traumatic as long-segment spinal fusion. It also has been shown to yield substantial anti-inflammatory effects in numerous animal models. Furthermore, auricular VNS has been extensively studied at Washington University School of Medicine in multiple neurological conditions, including aneurysmal subarachnoid hemorrhage, acute ischemic stroke, and intraparenchymal hemorrhage. The use of noninvasive VNS devices has been shown to be an intervention that is safely administered and does not cause undue distress to patients. Given these promising aspects of VNS, Washington University's particular interest in this treatment modality, and the unmet postoperative care needs for long-segment spinal fusion patients, the investigators propose prospectively studying the effects of auricular VNS in a population of patients at Barnes-Jewish Hospital who have undergone long-segment fusion surgeries. The investigators hypothesize that perioperative VNS will mitigate the systemic inflammatory reaction in these patients as demonstrated by reduced inflammatory markers (both direct and indirect) and improved inflammatory-mediated clinical outcomes.

This study will be a randomized controlled trial assessing differences between accepted perioperative care plus auricular VNS (the intervention) as compared to accepted perioperative care plus a sham stimulus. The VNS device will be a noninvasive stimulator applied to the left ear to stimulate the auricular branch of the vagus nerve. All patients will be fitted with the device, and the sham stimulus will not receive the required therapeutic stimulation through the device. Patients will receive stimulation twice on the day of surgery followed by twice daily during the duration of their postoperative hospital admission. Relevant inflammatory cytokines, laboratory tests, pain scores, clinical outcomes, and imaging studies will be obtained for each patient. Post-hospital disposition, delayed adverse outcomes, and hospital readmissions will also be tracked after discharge.

Being tested
Auricular vagus nerve stimulation, Sham Auricular Vagus nerve Stimulation
Keywords
spinal fusion, postoperative pain, glycemic control, inflammation, vagal nerve stimulation, postoperative complications, cytokine, spine surgery
Medical subject headings
Hyperglycemia, Spinal Diseases, Neurologic Manifestations, Nervous System Diseases, Inflammation, Pain, Postoperative, Postoperative Complications

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Auricular vagus nerve stimulationDevice

    Transcutaneous auricular vagal nerve stimulation

  • Sham Auricular Vagus nerve StimulationDevice

    Transcutaneous auricular vagal nerve stimulator applied without utilizing stimulating current.

Study groups in NCT07218133
Study groupRoleWhat they receive
Auricular vagal nerve stimulationExperimentalParticipants will receive vagal nerve stimulation twice on the day of surgery (once preoperatively) and twice daily postoperatively for duration of hospitalization. All patients will be fitted with the device via adhesive contacts to the left ear. Stimulation will occur for 20 minutes per session. The intervention will provide stimulation according to the following parameters: frequency 20 Hz, pulse width 250 µm, and fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation
Receives: Device: Auricular vagus nerve stimulation
Sham vagal nerve stimulationSham comparatorParticipants will have an auricular vagal nerve stimulator device applied in the same manner as the experimental arm, but they will not receive the actual stimulation.
Receives: Device: Sham Auricular Vagus nerve Stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Inflammatory cytokine levels

    The levels of 4 different inflammatory cytokines will be measured: interleukin-6 (IL-6), IL-1, IL-10, and tumor necrosis factor alpha (TNF-a) (all measured in pg/ml). Blood for these tests will be drawn preoperatively, postoperatively, on postop day 3, and postop day 6 (or time of discharge).

    Measured: 5-10 days (depending on hospital admission length)

Secondary outcomes (13)
  1. Pain scores

    Patient pain levels will be assessed twice daily using the visual analogue scale (VAS), a validated pain reporting scale that uses a 100-millimeter horizontal line with anchors at "no pain" (0) and "worst possible pain" (100). Patients draw a line along this spectrum to signify their pain level. Higher distance along the spectrum in a left-to-right direction indicates higher pain.

    Measured: 5-10 days (depending on hospital admission length)

  2. blood glucose levels

    Glucose measurements will be obtained multiple times daily via bedside point-of-care testing as well as through daily CMP labs (in mg/dL).

    Measured: 5-10 days (depending on hospital admission length)

  3. Postoperative adverse events/complications

    Investigators will track the incidence of postoperative adverse events or complications, including temporary radiculopathy or nerve stretch injury, deep vein thrombosis (DVT), pulmonary embolism (PE), acute kidney injury (AKI), ileus, wound healing problems, hospital delirium, transfusion reactions, and infections. All patients will receive screening lower extremity doppler (LED) studies before surgery and at time of hospital discharge.

    Measured: 5-10 days (depending on hospital admission length)

  4. Secondary markers of inflammation

    Daily laboratory studies that serve as surrogate markers for the body's degree of systemic inflammation will be obtained. This includes labs such as CRP, cortisol, creatinine, and troponin (all in mg/dL)

    Measured: 5-10 days (depending on hospital admission length)

  5. Post-hospitalization disposition

    Investigators will track patients' post-hospitalization disposition (e.g. home versus inpatient rehabilitation).

    Measured: 5-10 days (depending on hospital admission length)

  6. Heart rate

    Investigators will continuously monitor patients' heart rates to capture incidences of bradycardia that may be associated with the VNS intervention.

    Measured: Time Frame: 5-10 days (depending on hospital admission length)

  7. Opioid usage

    Patients' daily opioid usage will be recorded while hospitalized. Usage will be converted to morphine milligram equivalents (MME).

    Measured: 5-10 days (depending on hospital admission length)

  8. Insulin requirements

    Insulin requirements (units insulin) for patients during their hospital stay will be recorded.

    Measured: 5-10 days (depending on hospital admission length)

  9. Erythrocyte sedimentation rate (ESR)

    Postoperative ESR will be measured daily (in mm/hr) to assess systemic inflammation.

    Measured: 5-10 days (depending on hospital admission length)

  10. D-dimer levels

    D-dimer levels will be obtained postoperatively every other day (in microgram/mL)

    Measured: 5-10 days (depending on hospital admission length)]

  11. Hospital admission length

    Length of patient hospital stay after surgery will be recorded.

    Measured: 5-10 days (depending on hospital admission length)

  12. Blood pressure

    Tracking of blood pressure and temperature will allow investigators to evaluate the potential influence of VNS on blood pressure control for hypertensive patients and to determine if any hypotensive events are associated with the intervention.

    Measured: 5-10 days (depending on hospital admission length)]

  13. Readmission rates

    The incidence of hospital readmission within 30 days and 60 days will be recorded (yes versus no readmissions).

    Measured: 60 days postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2025
  2. Study start8 Oct 2025
  3. Primary completionJan 2027 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be assigned to either the vagal nerve stimulation arm or the sham stimulation arm.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07218133
Sponsor's protocol ID
202407057SpineVNS
Acronym
TAPIS
Status last verified
Sep 2025
First submitted
8 Oct 2025
Last updated
18 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in